[Thoracoscopic thymectomy for myasthenia gravis and non-invasive thymoma after COVID-19 pneumonia].
Evgeny B TopolnitskyV V GusakovPublished in: Khirurgiia (2024)
Modern guidelines have identified thoracoscopic thymectomy as a preferable option for myasthenia gravis and non-invasive thymoma. In the era of the new coronavirus infection, it is relevant to develop protocols for anesthetic and perioperative support of patients undergoing thymectomy for myasthenia gravis after COVID-associated pneumonia (CAP). We present the results of thoracoscopic thymectomies in patients after CAP. Multidisciplinary team should determine therapeutic support, the need for plasmapheresis and thymectomy. Plasmapheresis and glucocorticosteroids are effective in addition to anticholinesterase therapy at the stages of perioperative support for correction of neurological status in patients with myasthenia combined with chronic obstructive pulmonary disease and pulmonary hypertension. Outpatient direct anticoagulants are advisable considering the need for prolonged postoperative prevention of thrombotic events.
Keyphrases
- myasthenia gravis
- patients undergoing
- sars cov
- coronavirus disease
- chronic obstructive pulmonary disease
- pulmonary hypertension
- end stage renal disease
- cardiac surgery
- ejection fraction
- newly diagnosed
- chronic kidney disease
- robot assisted
- prognostic factors
- respiratory syndrome coronavirus
- thoracic surgery
- pulmonary artery
- quality improvement
- lung function
- patient reported outcomes
- clinical practice
- intensive care unit
- stem cells
- mesenchymal stem cells
- minimally invasive
- community acquired pneumonia